Literature DB >> 12196473

Preservation of pancreatic beta-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk hispanic women.

Thomas A Buchanan1, Anny H Xiang, Ruth K Peters, Siri L Kjos, Aura Marroquin, Jose Goico, Cesar Ochoa, Sylvia Tan, Kathleen Berkowitz, Howard N Hodis, Stanley P Azen.   

Abstract

Type 2 diabetes frequently results from progressive failure of pancreatic beta-cell function in the presence of chronic insulin resistance. We tested whether chronic amelioration of insulin resistance would preserve pancreatic beta-cell function and delay or prevent the onset of type 2 diabetes in high-risk Hispanic women. Women with previous gestational diabetes were randomized to placebo (n = 133) or the insulin-sensitizing drug troglitazone (400 mg/day; n = 133) administered in double-blind fashion. Fasting plasma glucose was measured every 3 months, and oral glucose tolerance tests (OGTTs) were performed annually to detect diabetes. Intravenous glucose tolerance tests (IVGTTs) were performed at baseline and 3 months later to identify early metabolic changes associated with any protection from diabetes. Women who did not develop diabetes during the trial returned for OGTTs and IVGTTs 8 months after study medications were stopped. During a median follow-up of 30 months on blinded medication, average annual diabetes incidence rates in the 236 women who returned for at least one follow-up visit were 12.1 and 5.4% in women assigned to placebo and troglitazone, respectively (P < 0.01). Protection from diabetes in the troglitazone group 1) was closely related to the degree of reduction in endogenous insulin requirements 3 months after randomization, 2) persisted 8 months after study medications were stopped, and 3) was associated with preservation of beta-cell compensation for insulin resistance. Treatment with troglitazone delayed or prevented the onset of type 2 diabetes in high-risk Hispanic women. The protective effect was associated with the preservation of pancreatic beta-cell function and appeared to be mediated by a reduction in the secretory demands placed on beta-cells by chronic insulin resistance.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12196473     DOI: 10.2337/diabetes.51.9.2796

Source DB:  PubMed          Journal:  Diabetes        ISSN: 0012-1797            Impact factor:   9.461


  286 in total

1.  Approach to the patient with gestational diabetes after delivery.

Authors:  Thomas A Buchanan; Kathleen A Page
Journal:  J Clin Endocrinol Metab       Date:  2011-12       Impact factor: 5.958

2.  The role of peroxisome proliferator-activated receptor γ in pancreatic β cell function and survival: therapeutic implications for the treatment of type 2 diabetes mellitus.

Authors:  D Gupta; T Kono; C Evans-Molina
Journal:  Diabetes Obes Metab       Date:  2010-12       Impact factor: 6.577

3.  Diabetes Prevention in high-risk women with gestational diabetes.

Authors:  Mary Ann Banerji
Journal:  Curr Diab Rep       Date:  2003-06       Impact factor: 4.810

Review 4.  The major diabetes prevention trials.

Authors:  Jaakko Tuomilehto; Jaana Lindström
Journal:  Curr Diab Rep       Date:  2003-04       Impact factor: 4.810

Review 5.  The metabolic syndrome in children and adolescents.

Authors:  Martha L Cruz; Michael I Goran
Journal:  Curr Diab Rep       Date:  2004-02       Impact factor: 4.810

Review 6.  Gene expression in the pathophysiology of type 2 diabetes mellitus.

Authors:  Mary-Elizabeth Patti
Journal:  Curr Diab Rep       Date:  2004-06       Impact factor: 4.810

7.  Aspirin use and risk of type 2 diabetes in apparently healthy men.

Authors:  Yasuaki Hayashino; Charles H Hennekens; Tobias Kurth
Journal:  Am J Med       Date:  2009-02-21       Impact factor: 4.965

Review 8.  Metabolic syndrome therapy: prevention of vascular injury by antidiabetic agents.

Authors:  Ligia J Dominguez; James R Sowers
Journal:  Curr Hypertens Rep       Date:  2005-04       Impact factor: 5.369

Review 9.  Prediabetes mellitus and its links to atherosclerosis.

Authors:  Daniel Kramer; Annaswamy Raji; Jorge Plutzky
Journal:  Curr Diab Rep       Date:  2003-02       Impact factor: 4.810

10.  Leptinomimetic effects of the AMP kinase activator AICAR in leptin-resistant rats: prevention of diabetes and ectopic lipid deposition.

Authors:  X Yu; S McCorkle; M Wang; Y Lee; J Li; A K Saha; R H Unger; N B Ruderman
Journal:  Diabetologia       Date:  2004-12-02       Impact factor: 10.122

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.